 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C34H52N4O8 |
| Molecular Weight | 644.7987 |
| Exact Mass | 644.378 |
| CAS # | 485395-71-9 |
| Related CAS # | Aminohexylgeldanamycin hydrochloride;1146534-45-3 |
| PubChem CID | 155971212 |
| Appearance | Purple to black solid powder |
| LogP | 2.5 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 46 |
| Complexity | 1250 |
| Defined Atom Stereocenter Count | 5 |
| SMILES | O(C([H])([H])[H])[C@]1([H])[C@@]([H])([C@@]([H])(C([H])([H])[H])C([H])=C(C([H])([H])[H])[C@@]([H])([C@]([H])(C([H])=C([H])C([H])=C(C([H])([H])[H])C(N([H])C2=C([H])C(C(=C(C2=O)C([H])([H])[C@@]([H])(C([H])([H])[H])C1([H])[H])N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])=O)=O)OC([H])([H])[H])OC(N([H])[H])=O)O[H] |c:16,31,t:27| |
| InChi Key | FEKZHEHNADINKB-YXGLCVOKSA-N |
| InChi Code | InChI=1S/C34H52N4O8/c1-20-16-24-29(37-15-10-8-7-9-14-35)26(39)19-25(31(24)41)38-33(42)21(2)12-11-13-27(44-5)32(46-34(36)43)23(4)18-22(3)30(40)28(17-20)45-6/h11-13,18-20,22,27-28,30,32,37,40H,7-10,14-17,35H2,1-6H3,(H2,36,43)(H,38,42)/b13-11-,21-12+,23-18+/t20-,22+,27+,28+,30-,32?/m1/s1 |
| Chemical Name | [(4E,6Z,8S,10E,12S,13R,14S,16R)-19-(6-aminohexylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | HSP90 |
| ln Vitro | In prostate cancer, HPMA copolymer-aminohexylgeldanamycin conjugates target cell surface expressed GRP78[2]. |
| References |
[1]. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release. 2011;151(3):263-270. [2]. HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer. Pharm Res. 2010;27(12):2683-2693. |
Solubility Data
| Solubility (In Vitro) | DMSO : 110 mg/mL (170.60 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.25 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.25 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5509 mL | 7.7543 mL | 15.5087 mL | |
| 5 mM | 0.3102 mL | 1.5509 mL | 3.1017 mL | |
| 10 mM | 0.1551 mL | 0.7754 mL | 1.5509 mL |